RCKT

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

Wall Street analysts forecast RCKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCKT is 9.83 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rocket Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Rocket Pharmaceuticals Inc. EPS for the last quarter amounts to -0.45 USD, decreased -36.62 % YoY.

Rocket Pharmaceuticals Inc (RCKT) has 299 emplpoyees as of January 10 2026.

Today RCKT has the market capitalization of 403.67M USD.